Feasibility and preliminary effectiveness of virtual reality as a patient education tool for people with cancer undergoing immunotherapy: a randomised controlled pilot study in a regional setting

Central West Cancer Care Centre, Orange Health Service0 个研究点目标入组 36 人开始时间: 2022年11月23日最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Patients will be eligible to participate if they meet the following criteria:
•a) are 18 years and over,
•b) are diagnosed with a reportable cancer of any stage (e.g., melanoma, kidney cancer, mesothelioma, lung cancer) that will be treated with immunotherapy alone,
•c) are due to start only immunotherapy agents (i.e., patients may not receive any other treatment, such as chemotherapy or radiotherapy),
•d) are able to understand English, and
•e) are able to give their own consent.

•Patients will be excluded if they:
•a) have a condition that interferes with VR usage, including but not limited to seizures, facial injury precluding safe placement of headset, and visual impairments;
•b) have a prognosis of <3 months from the time of enrolment per treating oncologist or;
•c) receiving other systemic cancer therapies in combination with immunotherapy
•d) have a pre-existing severe mental health diagnosis or significant cognitive impairment, such as severe dementia that would impair their comprehension and/or ability to provide informed consent

发起方

Central West Cancer Care Centre, Orange Health Service